In this randomized trial of patients with recurrent Cdiff, fidaxomicin was equivalent to vancomycin for clinical cure rate, but fidaxomicin had significantly fewer recurrences than vancomycin. Use of this agent in clinical practice will depend on FDA approval and comparative cost (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.